In this QCast episode, co-hosts Jullia and Tom explore medical device clinical trials and why they require a different development approach from drug studies. They clarify what these trials mean in practical terms: medical device clinical trials are designed to generate evidence on safety, performance, and clinical benefit in people, but the exact evidence needed depends heavily on the type of device, its intended use, and its risk profile. The conversation focuses on where these studies matter most, including early feasibility work, pivotal evidence generation, usability in real clinical settings, and the operational controls needed to support credible results.
They also discuss why device development often follows a more iterative path than pharmaceutical development, how classification and intended claims shape study design, and what tends to determine whether a device trial produces reliable, decision-ready evidence. Along the way, Jullia and Tom highlight common pressure points such as weak traceability between device versions, inconsistent site training, poor device accountability, and data capture issues tied to real-world use. They also look at the practical value these studies provide, including stronger evidence for safety and performance, better alignment between clinical and regulatory strategy, and a clearer basis for post-market evidence generation.
🎧 Listen to the Episode:
Key Takeaways
What Medical Device Clinical Trials Are Designed to Show
Medical device clinical trials are built to generate evidence on safety, performance, and clinical benefit in the setting where the device will actually be used. That evidence can look quite different depending on the product, because an implant, a diagnostic device, a software-enabled tool, and a procedural device do not raise the same clinical or operational questions.
Why Study Design Depends So Heavily on the Device
Device trials are shaped by intended use, classification, risk, and how the product is used in practice. Early studies may focus on feasibility, procedural consistency, or usability, while later studies may need to demonstrate more robust clinical performance and longer-term safety. This means teams need a development strategy that reflects the actual device rather than borrowing assumptions from drug trial models.
What Makes Device Trials Work in Practice
Strong execution depends on clear training, tight device accountability, reliable traceability, and study procedures that fit the clinical setting. Teams need to control how the device is handled, used, documented, and linked to participant data throughout the study. When those operational details are planned well, device trials are far more likely to produce credible evidence that supports both near-term decisions and longer-term regulatory expectations.
Full Transcript
Jullia
Welcome to QCast, the show where biometric expertise meets data-driven dialogue. I’m Jullia.
Tom
I’m Tom, and in each episode, we dive into the methodologies, case studies, regulatory shifts, and industry trends shaping modern drug development.
Jullia
Whether you’re in biotech, pharma or life sciences, we’re here to bring you practical insights straight from a leading biometrics CRO. Let’s get started.
Tom
Today we’re looking at medical device clinical trials, and this is one of those topics where people often assume the trial model is basically the same as for medicines. It really isn’t. The evidence questions, the practical constraints, and even the way the product evolves can all be quite different. So to start simply, what is a medical device clinical trial actually trying to show?
Jullia
Well at the simplest level, it’s there to generate clinical evidence on safety, performance, and clinical benefit for a device in people. That sounds straightforward, but the shape of the evidence depends heavily on the device itself, because a wound dressing, a diagnostic platform, a surgical tool, and an implant do not raise the same questions.
So what matters early is getting clear on two things. First, is the product definitely being regulated as a medical device. Second, what claims is the evidence expected to support. Once those points are settled, the rest of the programme starts to make more sense, because endpoints, follow-up, oversight, and even site selection all flow from that.
Tom
I think that question about claims is a useful anchor, because it stops teams drifting into a generic study design. Now where do you see the biggest difference from drug trials once planning starts?
Jullia
Well one major difference is that devices often develop in a more iterative way. A drug’s composition is usually fixed by the time you reach clinical testing, but a device may still be going through controlled refinements around usability, engineering, or manufacturing. That means trial teams need very clear traceability between device versions and the data collected on each version.
Then you also see different endpoint mixes. Clinical outcomes still matter, of course, but teams may also need evidence on technical performance, functional improvement, or usability. For example, a common scenario is a device that works as intended from an engineering point of view, but the study still has to show clinicians can use it consistently and safely in the real care setting.
Tom
And that’s where people can get caught, because they hear “clinical trial” and picture a standard phase pathway, placebo control, and a familiar statistical frame. But device development tends to be staged differently, doesn’t it?
Jullia
It does. So you usually see stages tied to the maturity of the device and the decision that needs to be made next. Early work may focus on initial safety, basic performance, and whether the device can actually be used as intended in a clinical environment. Then you move into feasibility work, where teams refine endpoints, procedures, and patient selection, and after that you may have a more formal pivotal study that supports approval or market access.
Now that staged approach matters because each step should answer a specific question. Can the device be used safely. Does it perform consistently. Are the chosen endpoints realistic. Is the population defined properly? If a team rushes past those questions, the pivotal study can become much harder to run and harder to defend.
Tom
Can you give a concrete example of that?
Jullia
Yes, so imagine a study for an interventional device where the procedure itself needs a very specific technique. In an early or feasibility setting, you may realise the visit schedule is workable, but the training package for investigators is too light and the procedural variation is wider than expected. Now that has a knock-on effect on endpoint reliability.
Or take a software-enabled device collecting repeated measurements, for example. The device may function well, but the team learns that data uploads from site are inconsistent, timestamps need tighter control, or users interpret one instruction differently. Those details sound small, but they shape whether the later study generates clean, credible evidence.
Tom
So how much does device classification influence all this?
Jullia
A lot, and it should influence planning from the beginning, not just appear as a label near submission. Classification reflects risk, and risk affects the level of scrutiny, the strength of evidence expected, and the practical controls needed around the study. Higher-risk devices generally call for more robust prospective evidence, closer oversight, and stronger justification that the expected benefits outweigh the residual risks.
You tend to see that in everything from study size to follow-up duration. Some lower-risk products may rely more heavily on performance data, existing evidence, or literature. While higher-risk or implantable devices often need longer observation to understand and long-term safety and durability. Classification shapes the whole development strategy.
Tom
Now what tends to go wrong once the study is live?
Jullia
Well recruitment can be tougher than teams expect. Eligibility may depend on anatomy, procedure suitability, disease stage, or access to a specialist setting. And if the device involves an invasive procedure, the consent conversation is also more demanding, because patients need a clear understanding of both the clinical intervention and the investigational element.
Then there’s device control at site, which is fundamental. Sites need to know what they received, where it was stored, who used it, which participant received which device, and what happened to unused or returned units. If accountability logs are weak, or if identifiers are not recorded properly, you create traceability problems very quickly. That can affect safety review, data interpretation, and inspection readiness all at once.
Tom
So essentially, the device itself becomes part of the study data story rather than a separate logistics issue?
Jullia
Exactly, and the investigator responsibilities reflect that. Investigators are responsible for participant care and protocol compliance, but in device studies they also need tight control over how the device is used in line with the approved study documents. That can include restrictions on who is allowed to use it, how the procedure is performed, and what documentation is required at each step.
But one place teams get caught is assuming standard site processes will cover everything. Sometimes they won’t. A study may need device-specific training, procedure checklists, storage controls, or extra reconciliation steps. For example, if there is a dosing change in a drug trial, you track that through drug accountability and source records. In a device study, the equivalent issue might be a component replacement, a software update, or a procedural deviation, and each of those needs clear handling and documentation.
Tom
There’s also a wider evidence question here, because approval is rarely the end of the story for devices. Is it true that post-market evidence carries real weight?
Jullia
Yes, and that lifecycle view is one of the defining features of device evidence generation. Teams often need a plan that supports pre-market and post-market use of the evidence, especially where long-term performance, durability, or routine-use safety still need to be characterised after approval.
So that means data quality and traceability standards have to hold up over time. Current expectations across major regulatory frameworks place a lot of emphasis on proportionate design, data integrity, participant protection, and documented oversight. For device teams, that translates into building studies that are realistic for the setting, while still giving regulators, ethics committees, and internal stakeholders confidence in what the evidence actually shows.
Tom
Now if someone listening is planning a medical device trial now, what are the takeaways they should carry into the first serious planning meeting?
Jullia
So I’d keep it to four points. Start with classification, intended use, and the exact claims the study needs to support. Build the design around the device’s real-world use, including procedure, training, usability, and follow-up. Make device accountability and traceability part of the core study plan, not a side process. And test the operational model early, because issues with site workflow, data capture, or procedural consistency usually become visible before they become expensive.
Prioritising those will give teams a much better base. They help avoid borrowed assumptions from drug development, and they make it easier to generate evidence that is proportionate, credible, and usable later.
Ultimately, device trials work best when the design reflects the actual product, the risk profile, and the setting in which it will be used. Strong evidence depends on more than endpoints alone. It also depends on traceability, site execution, and clear control of the investigational device throughout the study.
Jullia
With that, we’ve come to the end of today’s episode on medical device clinical trials. If you found this discussion useful, don’t forget to subscribe to QCast so you never miss an episode and share it with a colleague. And if you’d like to learn more about how Quanticate supports data-driven solutions in clinical trials, head to our website or get in touch.
Tom
Thanks for tuning in, and we’ll see you in the next episode.
About QCast
QCast by Quanticate is the podcast for biotech, pharma, and life science leaders looking to deepen their understanding of biometrics and modern drug development. Join co-hosts Tom and Jullia as they explore methodologies, case studies, regulatory shifts, and industry trends shaping the future of clinical research. Where biometric expertise meets data-driven dialogue, QCast delivers practical insights and thought leadership to inform your next breakthrough.
Subscribe to QCast on Apple Podcasts or Spotify to never miss an episode.
